ASTALLTD.BO · BSE
ASTAL LABORATORIES LIMITED
₹70.22
+0.86% (+₹0.6)
Prev. close
₹69.62
Volume
8,029
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About ASTAL LABORATORIES LIMITED
Astal Laboratories Limited manufactures and sells pharmaceutical intermediates and bulk drugs in India. The company was formerly known as Macro International Limited and changed its name to Astal Laboratories Limited in April 2024. Astal Laboratories Limited was incorporated in 1993 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Balayogiswara Rao Peddinti
Headquarters
Hyderabad
Employees
22
Website
astallabs.comExchange
View on BSE ↗Key stats
Market cap
₹307.56 Cr
P/E ratio (TTM)
8.5
EPS (TTM)
₹8.25
Beta (1Y · daily vs NIFTY 50)
0.35
Beta (5Y · monthly vs NIFTY 50)
0.06
Shares float
2.39 Cr
EPS · quarter ended Jun 2026
₹2.18
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹3.43 Cr | ₹23.65 Cr | ₹64.23 Cr | ₹249.13 Cr | |
| EBITDA | ₹4.00 L | ₹1.13 Cr | ₹12.82 Cr | ₹20.99 Cr |
| ₹1.64 L | ₹78.47 L | ₹8.93 Cr | ₹14.71 Cr | |
| Diluted EPS | ₹0.04 | ₹1.55 | ₹8.04 | ₹7.81 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹9.91 Cr | ₹36.61 Cr | ₹63.34 Cr | ₹518.74 Cr | |
| ₹0 | ₹31.22 L | ₹13.27 Cr | ₹49.89 Cr | |
| Stockholders' equity | ₹5.18 Cr | ₹23.34 Cr | ₹35.99 Cr | ₹333.76 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-1.44 Cr | ₹-5.58 Cr | ₹-12.52 Cr | ₹-17.70 Cr | |
| Investing cash flow | ₹1.50 Cr | ₹-6.11 Cr | ₹-7.81 Cr | ₹-2.17 Cr |
| ₹0 | ₹17.68 Cr | ₹3.29 Cr | ₹2.58 Cr | |
| Capital expenditure | — | ₹-5.92 Cr | ₹-7.84 Cr | ₹-2.46 Cr |
| End cash position | ₹8.44 L | ₹6.08 Cr | ₹-10.96 Cr | ₹-28.25 Cr |
Capital expenditure has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| ASTAL LABORATORIES LIMITED | ₹304.93 Cr | ₹70.29 | 8.4 | 0.91 | 4.4% | 0.15 | +289.5% | -14.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Astal Laboratories standalone net profit rises 77.51% in the June 2026 quarter
Business Standard · 1 month ago